SML2014

Deracoxib

≥98% (HPLC)

• Sinónimos: 4-[3-(Difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide, 4-[5-(3-Fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC-046, SC-46, SC-59046
• Fórmula empírica (notación de Hill): C₁₇H₁₄F₃N₃O₃S
• Número CAS: 169590-41-4
• Peso molecular: 397.37
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Propiedades

• assay: ≥98% (HPLC)
• form: powder
• color: white to brown
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: room temp
• SMILES string: FC(F)c1n[n](c(c1)c3cc(c(cc3)OC)F)c2ccc(cc2)[S](=O)(=O)N
• InChI: 1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)
• InChI key: WAZQAZKAZLXFMK-UHFFFAOYSA-N

Descripción

Biochem/physiol Actions

Deracoxib is an orally active cyclooxygenase-2 (COX-2) inhibitor with >48-fold selectivity over COX-1 (IC50 of 203-189 nM against COX-2-dependent PGE2 production vs. IC50 of 9.85-9.96 μM against COX-1-dependent TxB2 production in dog whole blood). Deracoxib is also reported to exhibit inhibitory activity against phosphodiesterase (Ki = 3.6 μM against human PDE4D3) as well as positive modulatory effiacy toward 2-APB-stimulated transient receptor potential vanilloid 3 channel (TRPV3) activity.

Orally active COX-2 inhibitor with >48-fold selectivity over COX-1. Also inhibits PDE4D3 and enhances 2-APB-stimulated TRPV3 activity.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable